Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q3 FY25 Earnings Presentation
15 slides from Eris Lifesciences's earnings presentation, Feb 4, 2025
Slide 1: Eris Lifesciences filing cover letter to stock exchanges
EY Entrepreneur of the yea,2013 FROST & SULLIVAN Best Practices-2013 ElusIness today(YES bank Excellence Awards-2013 Eris Eris Lifesciences Limited Date: 04 February February 2025 To To BSE Limited National Stock Exchange Exchange of ofIndia India Limited Limited Phiroze Jeejeebhoy Towers Exchange P
Slide 2: Q3 FY25 and 9M FY25 Investor Presentation
Eris ERIS LIFESCIENCES LIMITED Q3 Q3 FY FY 2525 and 9M FY and 9M FY 25 25 INVESTOR INVESTOR PRESENTATION PRESENTATION 4 th Feb 4th Feb 2025 2025 1 Eris
Slide 3: Domestic Branded Formulations – 12% Organic Growth in Q3
DOMESTIC DOMESTIC BRANDED BRANDED FORMULATIONS FORMULATIONS–-12% 12%ORGANIC ORGANIC GROWTH GROWTH IN IN Q3 Q3 DBF DBFHeadline Headline Financials Financials DBF DBFBusiness Business Highlights Highlights Op Op Revenue Revenue •• Organic Organic DBF DBFgrowth growthbounces back to bounces back to 12%
Slide 4: Total Domestic Branded Formulations P&L – Q3 and 9M FY25
• TOTAL DOMESTIC TOTAL DOMESTICBRANDED BRANDEDFORMULATIONS FORMULATIONSP&L P&L– -Q3 Q3and and 9M 9M FY25 FY25 Q3 FY25 Q3 FY25 Q3 Q3FY24 Growth% 9M FY24 Growth% 9M FY25 FY25 9M 9MFY24 FY24 Growth Growth% % INR Crores Revenue from Revenue from Operations Operations 635 635 471 471 35% 35% 1,911 1,911
Slide 5: Gearing Up to Leverage the Market Opportunity in GLP-1
GEARING UP GEARING U r 0TO LEVERAGETHE LEVERAGE THEMARKET MARKET OPPORTUNITY OPPORTUNITY IN IN GLP-1 GLP-1 Our “Right Our "Right to Win” to Win" ▪• We We have have entered entered a strategic partnership a strategic partnership for for the launch of the launch of We will We will leverage Eris’ lever
Slide 6: New Product Launches from Our R&D Pipeline Driving Growth
NEW PRODUCT NEW PRODUCT LAUNCHES LAUNCHES FROM FROM OUR OUR R&D R&D PIPELINE PIPELINE DRIVING DRIVING GROWTH GROWTH •• First-in-market First-in-market combinations combinations of of Dapagliflozin Dapagliflozin from from our our R&D R&D pipeline launched in pipeline launched in Q3 FY25 Q3 FY25 –- aa
Slide 7: Globally Compliant Manufacturing Sites to Open Up New Growth Levers
• GLOBALLY COMPLIANT GLOBALLY COMPLIANT MANUFACTURING MANUFACTURINGSITES SITES TO TO OPEN OPEN UP NEW GROWTH UP NEW GROWTH LEVERS LEVERS ▪• Bhopal Bhopal facility facility –- "Form-Fill-Finish" “Form-Fill-Finish” of ofInsulins Insulinsto to be be operational inFY26 operational in FY26 Technology tra
Slide 8: Swiss Parenterals – Q3 and 9M Business and Financial Update
• SWISS PARENTERALS SWISS PARENTERALS –- Q3 Q3AND AND9M 9MBUSINESS BUSINESSAND ANDFINANCIAL FINANCIAL UPDATE UPDATE Financial Financial Performance Performance of of Base Base Business Business -–RoW RoW Injectable Exports Injectable Exports Revenue Revenue --INR INR Crore Crore EBIDTA EBIDTA-- INR
Slide 9: Significantly Ahead of Guidance in Debt Reduction
SIGNIFICANTLY AHEAD SIGNIFICANTLY AHEAD OF OF GUIDANCE GUIDANCE IN DEBT REDUCTION IN DEBT REDUCTION Plan n shared shared at at the th start of FY25 Outlook at the end of Q3 FY25 FY25E Net •• FY25E Net Debt Debt -,~ INR INR 2,100 cr. 2,100 cr. vs. vs. guidance guidance INRINR Debt to Debt toEBIDTA EB
Slide 10: Acquisitions Starting to Deliver; EPS Inflection Starting FY26
ACQUISITIONS STARTING ACQUISITIONS STARTING TO TO DELIVER; DELIVER; TO TO DRIVE DRIVE EPS INFLECTION STARTING EPS INFLECTION STARTING FY26 FY26 1 Last Last 44 years’ years' Investment Cycle Investment Cycle Outlook -– FY26 Outlook FY26 and and Beyond Beyond FY FY 22 22 FY FY 25 E 25 E •• Inflection
Slide 11: ROCE Trajectory Seen Improving in Tandem; To Exceed 20% in FY27
ROCE TRAJECTORY ROCE TRAJECTORYSEEN SEENIMPROVING IMPROVINGIN IN TANDEM; TANDEM; TO TO EXCEED EXCEED20% 20% IN FY27 IN FY27 Key Key Levers at Work Levers at Work Return On Capital Return On Capital Employed Employed(ROCE) (ROCE) Value creation ▪■ Value creationfrom fromacq acquired u i red 22%* 20%*
Slide 12: Consolidated P&L Q3 FY25 – Fixed Cost Synergies Continue to Accrue
• CONSOLIDATED P&L CONSOLIDATED Q3 FY25 P&L Q3 FY25 -–FIXED FIXEDCOST COSTSYNERGIES SYNERGIES CONTINUE CONTINUETO TOACCRUE ACCRUE • 4. Consolidated Consolidated Q3 FY 25 9M FY 25 Q3 FY Q3 FY 25 25 Q3 Q3 FY FY24 24 Q3 FY 25 9M FY 9M FY 25 25 9M FY 9M FY24 24 9M FY 25 •• Q3 Q3 consolidated consolidate
Slide 13: Shareholder Profile
SHAREHOLDER PROFILE SHAREHOLDER PROFILE Shareholding of Shareholding of Promoters Promoters and and Top Top 15 15 Institutional Institutional Investors Investors Shareholding Pattern Shareholding Pattern 31-Dec-24 31-Dec-24 30-Sep-24 30-Sep-24 30-Jun-24 30-Jun-24 Name of Name of Shareholder Sharehol
Slide 14: Safe Harbor Statement
SAFE HARBOR SAFE HARBOR STATEMENT STATEMENT This presentation This presentation contains contains forward-looking forward-looking statements statements and information that and information that involve involve risks, risks, uncertainties uncertainties and and assumptions. Forward-looking assumptions
Slide 15: Thank You
Eris ERIS LIFESCIENCES LIMITED THANK YOU THANK YOU KRUTI RAVAL KRUTI RAVAL INVESTOR INVESTOR RELATIONS RELATIONS kruti@erislifesciences.com kruti@erislifesciences.com 14 Eris Lifesciences